Fund Holdings — Bain Capital Life Sciences Investors, LLC

Total Portfolio Value:
$1.11B
Total Bought:
$87.41M
Total Sold:
$267.53M
Net Transaction:
-$180.12M
Securities
▲▼
SharesValue
Q4 2025
▲▼
Q1 2026
▲▼
Change
▲▼
Q4 2025
▲▼
Q1 2026
▲▼
Weight (%)
▲▼
Change
▲▼
Heartflow, Inc.(HTFL)12,448,15810,448,158-2,000,000$362.86M$254.20M22.93%-$108.66M
Newamsterdam Pharma Company
ORDINARY SHARES
7,306,5667,306,5660$256.31M$233.88M21.09%-$22.43M
Olema Pharmaceuticals, Inc.(OLMA)8,508,6417,473,238-1,035,403$212.72M$111.43M10.05%-$101.29M
Savara Inc.(SVRA)17,600,62117,600,6210$106.13M$96.10M8.67%-$10.03M
Pharvaris N V
COM
2,802,0812,675,509-126,572$77.76M$75.58M6.82%-$2.17M
Solid Biosciences Inc7,911,6699,808,819+1,897,150$44.62M$70.62M6.37%+$26.00M
X4 Pharmaceuticals, Inc.(XFOR)7,967,4547,967,4540$31.87M$32.91M2.97%+$1.04M
Dianthus Therapeutics, Inc.(DNTH)743,592362,470-381,122$30.64M$30.42M2.74%-$224.9K
Annexon, Inc.(ANNX)5,249,0695,212,674-36,395$26.35M$28.88M2.60%+$2.53M
Kyverna Therapeutics, Inc.(KYTX)3,110,0003,110,0000$29.23M$26.84M2.42%-$2.39M
Cabaletta Bio, Inc.(CABA)9,677,1259,677,1250$21.19M$26.03M2.35%+$4.84M
Centessa PharmaceuticalsADS0635,000+635,000$0$25.22M2.27%+$25.22M
Alkermes plcSHS(ALKS)0610,000+610,000$0$21.57M1.95%+$21.57M
Rapid Micro Biosystems, Inc.CL A(RPID)8,434,5608,434,5600$24.46M$19.15M1.73%-$5.31M
C4 Therapeutics, Inc.(CCCC)7,171,9107,171,9100$13.70M$18.86M1.70%+$5.16M
Atea Pharmaceuticals, Inc.(AVIR)2,485,6382,360,638-125,000$8.87M$12.70M1.15%+$3.83M
Disc Medicine, Inc.(IRON)0141,234+141,234$0$9.03M0.81%+$9.03M
Upstream Bio, Inc.(UPB)1,329,544867,211-462,333$36.10M$7.80M0.70%-$28.29M
Xilio Therapeutics, Inc.(XLO)0664,021+664,021$0$5.58M0.50%+$5.58M
Newamsterdam Pharma CompanyW EXP 99 99 999
*W EXP 99/99/999
99,99999,9990$2.30M$2.00M0.18%-$296.0K
Mersana Therapeutics Inc346,5450-346,545$10.03M$0—-$10.03M
Tango Therapeutics, Inc.(TNGX)653,4930-653,493$5.79M$0—-$5.79M
Xilio Therapeutics, Inc.(XLO)7,372,6860-7,372,686$4.72M$0—-$4.72M
Page 1 of 1
Bain Capital Life Sciences Investors, LLC — 13F Holdings — Q1 2026 | TickerTrail